Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE)...